![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Neuroscience-WP (J.A.O., W.L., T.-B.C., R.S.L.C., M.A.J., C.S., D.J.P., P.J.C., D.L.W.) and Medicinal Chemistry (C.W.L.), Merck Research Laboratories, West Point, Pennsylvania; Molecular Systems, Merck Research Laboratories, Rahway, New Jersey (S.N.H.); and Neurobiology, Merck Research Laboratories, San Diego, California (H.J.S.)
We have identified a family of highly selective allosteric modulators of the group I metabotropic glutamate receptor subtype 5 (mGluR5). This family of closely related analogs exerts a spectrum of effects, ranging from positive to negative allosteric modulation, and includes compounds that do not themselves modulate mGluR5 agonist activity but rather prevent other family members from exerting their modulatory effects. 3,3'-Difluorobenzaldazine (DFB) has no agonist activity, but it acts as a selective positive allosteric modulator of human and rat mGluR5. DFB potentiates threshold responses to glutamate, quisqualate, and 3,5-dihydroxyphenylglycine in fluorometric Ca2+ assays 3- to 6-fold, with EC50 values in the 2 to 5 µM range, and at 10 to 100 µM, it shifts mGluR5 agonist concentration-response curves approximately 2-fold to the left. The analog 3,3'-dimethoxybenzaldazine (DMeOB) acts as a negative modulator of mGluR5 agonist activity, with an IC50 of 3 µM in fluorometric Ca2+ assays, whereas the analog 3,3'-dichlorobenzaldazine (DCB) does not exert any apparent modulatory effect on mGluR5 activity. However, DCB seems to act as an allosteric ligand with neutral cooperativity, preventing the positive allosteric modulation of mGluRs by DFB as well as the negative modulatory effect of DMeOB. None of these analogs affects binding of [3H]quisqualate to the orthosteric (glutamate) site, but they do inhibit [3H]3-methoxy-5-(2-pyridinylethynyl)pyridine binding to the site for 2-methyl-6-(phenylethynyl)-pyridine, a previously identified negative allosteric modulator. With the use of these compounds, we provide evidence that allosteric sites on GPCRs can respond to closely related ligands with a range of pharmacological activities from positive to negative modulation as well as to neutral competition of this modulation.
Address correspondence to: Dr. David L. Williams, Jr., WP46-300, Merck Research Laboratories, West Point, PA 19486. E-mail: david_williams1{at}merck.com
This article has been cited by other articles:
|
|
 |
|
  Y. Chen, C. Goudet, J.-P. Pin, and P. J. Conn N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors Mol. Pharmacol., March 1, 2008; 73(3): 909 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Langmead Screening for Positive Allosteric Modulators: Assessment of Modulator Concentration-Response Curves as a Screening Paradigm J Biomol Screen, August 1, 2007; 12(5): 668 - 676. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Hemstapat, H. Da Costa, Y. Nong, A. E. Brady, Q. Luo, C. M. Niswender, G. D. Tamagnan, and P. J. Conn A Novel Family of Potent Negative Allosteric Modulators of Group II Metabotropic Glutamate Receptors J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 254 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, T. de Paulis, J.-P. Pin, and P. J. Conn Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses Mol. Pharmacol., May 1, 2007; 71(5): 1389 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hemstapat, T. de Paulis, Y. Chen, A. E. Brady, V. K. Grover, D. Alagille, G. D. Tamagnan, and P. J. Conn A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators Mol. Pharmacol., August 1, 2006; 70(2): 616 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Conn and C. M. Niswender mGluR7's lucky number PNAS, January 10, 2006; 103(2): 251 - 252. [Full Text] [PDF]
|
|
|
|
|
|
Patrick. M. Downey, G. Lozza, R. Petro, E. Diodato, C. Foglia, F. Bottazzoli, R. Brusa, T. Asquini, A. Reggiani, and M. Grilli Ecdysone-Based System for Controlled Inducible Expression of Metabotropic Glutamate Receptor Subtypes 2, 5, and 8 J Biomol Screen, December 1, 2005; 10(8): 841 - 848. [Abstract] [PDF]
|
|
|
|
|
|
Y. Zhang, A. L. Rodriguez, and P. J. Conn Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1212 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Rodriguez, Y. Nong, N. K. Sekaran, D. Alagille, G. D. Tamagnan, and P. J. Conn A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators Mol. Pharmacol., December 1, 2005; 68(6): 1793 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Goudet, J. Kniazeff, V. Hlavackova, F. Malhaire, D. Maurel, F. Acher, J. Blahos, L. Prezeau, and J.-P. Pin Asymmetric Functioning of Dimeric Metabotropic Glutamate Receptors Disclosed by Positive Allosteric Modulators J. Biol. Chem., July 1, 2005; 280(26): 24380 - 24385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Kinney, J. A. O'Brien, W. Lemaire, M. Burno, D. J. Bickel, M. K. Clements, T.-B. Chen, D. D. Wisnoski, C. W. Lindsley, P. R. Tiller, et al. A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 199 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Binet, C. Brajon, L. Le Corre, F. Acher, J.-P. Pin, and L. Prezeau The Heptahelical Domain of GABAB2 Is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABAB Receptor J. Biol. Chem., July 9, 2004; 279(28): 29085 - 29091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. O'Brien, W. Lemaire, M. Wittmann, M. A. Jacobson, S. N. Ha, D. D. Wisnoski, C. W. Lindsley, H. J. Schaffhauser, B. Rowe, C. Sur, et al. A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 568 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Goudet, F. Gaven, J. Kniazeff, C. Vol, J. Liu, M. Cohen-Gonsaud, F. Acher, L. Prezeau, and J. P. Pin Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors PNAS, January 6, 2004; 101(1): 378 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Marino, D. L. Williams Jr., J. A. O'Brien, O. Valenti, T. P. McDonald, M. K. Clements, R. Wang, A. G. DiLella, J. F. Hess, G. G. Kinney, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment PNAS, November 11, 2003; 100(23): 13668 - 13673. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
